by Symmetron | Jan 22, 2019
juvenile idiopathic arthritis  Indirect comparison of ACR response of biologic treatments in active SJIA Presented at the Annual European Congress of Rheumatology. June 6-9, 2012. Berlin, Germany Authors Diamantopoulos A, LeReun C, Westhovens R, Dejonckheere F...
by Symmetron | Jan 21, 2019
juvenile idiopathic arthritis  Tocilizumab in polyarticular juvenile idiopathic arthritis: a cost-utility model for the United Kingdom Value in Health. 2013;16(7):A564 Authors Chang S, Sawyer L, Dejonckheere F, van Suijlekom-Smit LW, Anink J, Diamantopoulos A Process...
by Symmetron | Jan 21, 2019
juvenile idiopathic arthritis  Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland Annals of the Rheumatic Diseases. 2013;71:258-259 Authors Hallinen T, Soini EJ, Diamantopoulos A, Dejonckheere F, Vihervaara V, Hautala A,...
Recent Comments